|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 16/09/14 | CHUGAI PHARMACEUTICAL : Roche's $8 billion InterMune buy not a signal for more big deals | RE |
| 04/09/14 | Roche : rules out mega deals, open to smaller ones - paper | RE |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Thompson
CEO | Chief Executive Officer | 57 | - |
| Chief Tech/Sci/R&D Officer | 71 | 31/03/2002 | |
Carla Fiankan
LAW | General Counsel | - | 31/07/2011 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.58% | +5.21% | +11.08% | +36.79% | 47.97B | ||
| -1.69% | +1.48% | +50.57% | +33.71% | 44.5B | ||
| +2.56% | +7.34% | +366.69% | +609.24% | 43.93B | ||
| +0.24% | +2.85% | +10.67% | +87.77% | 41.03B | ||
| -0.62% | -1.11% | +4.65% | +46.13% | 29.85B | ||
| -0.28% | +1.07% | +24.58% | +149.55% | 17.27B | ||
| +3.37% | +9.21% | +8.32% | - | 15.34B | ||
| +1.16% | +0.26% | +28.72% | +47.55% | 15.3B | ||
| -2.21% | -4.70% | - | - | 14.82B | ||
| Average | +0.47% | +2.35% | +63.16% | +144.39% | 30B | |
| Weighted average by Cap. | +0.53% | +2.86% | +80.17% | +159.75% |
- Stock Market
- Stocks
- Stock
Select your edition
All financial news and data tailored to specific country editions
















